These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 14412284)

  • 21. The relationsip between the anti-hallucinatory effect and extrapyramidal symptoms induced by fluphenazine. (A study in 40 chronic schizophrenics).
    KRUSE W
    Curr Ther Res Clin Exp; 1961 Jan; 3():19-22. PubMed ID: 13754636
    [No Abstract]   [Full Text] [Related]  

  • 22. [Use in psychiatry of antiparkinson drugs].
    Bourgeois M; Mazaux JM; Imbert D; Daubech MJ; Daulouède JP; Tignol J
    Ann Med Psychol (Paris); 1976 Oct; 2(3):499-510. PubMed ID: 1020859
    [No Abstract]   [Full Text] [Related]  

  • 23. The use of amphetamine induced stereotyped behaviour as a model for the experimental evaluation of antiparkinson agents.
    Costall B; Naylor RJ; Wright T
    Arzneimittelforschung; 1972 Jul; 22(7):1178-83. PubMed ID: 4404343
    [No Abstract]   [Full Text] [Related]  

  • 24. [SOME REMARKS ON THE INDICATIONS FOR UK-738 (PONALIDE) AS A CORRECTOR OF EXTRAPYRAMIDAL DISORDERS DUE TO NEUROLEPTICS].
    BORENSTEIN P; BLES G
    Gaz Med Fr; 1964 May; 71():2075. PubMed ID: 14144655
    [No Abstract]   [Full Text] [Related]  

  • 25. [Effects of tranquilizing drugs (reserpine, chlorpromazine) on extrapyramidal motility disorders].
    BRANDER E
    Monatsschr Psychiatr Neurol; 1956; 132(2-3):81-95. PubMed ID: 13369436
    [No Abstract]   [Full Text] [Related]  

  • 26. [Extrapyramidal tract diseases].
    KASE M
    Naika; 1962 Dec; 10():1060-2. PubMed ID: 13962660
    [No Abstract]   [Full Text] [Related]  

  • 27. Antiparkinson medication in the treatment of extrapyramidal side effects: single of multiple daily doses?
    Neu C; Dimascio A; Demirgian E
    Curr Ther Res Clin Exp; 1972 May; 14(5):246-51. PubMed ID: 4623975
    [No Abstract]   [Full Text] [Related]  

  • 28. [Effect of a new phenothiazine derivative--fluophenazine--on extrapyramidal manifestations of a hyperkinetic type].
    REBUCCI GG
    G Psichiatr Neuropatol; 1962; 90():269-82. PubMed ID: 14490858
    [No Abstract]   [Full Text] [Related]  

  • 29. Phenothiazine ataraxics. Extrapyramidal reactions.
    CAIN HD; MALCOLM M
    Calif Med; 1960 Jul; 93(1):24-8. PubMed ID: 13806816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Study of the delayed-action form of a synthetic antiparkinsonian drug: Akineton].
    Kammerer T; Schweitzer-Bucher E; Jamet P; Royer M
    Ann Med Psychol (Paris); 1972 May; 1(5):688-96. PubMed ID: 5081112
    [No Abstract]   [Full Text] [Related]  

  • 31. Recognition and management of drug-induced extra-pyramidal reactions and "paradoxical" behavioural reactions in psychiatry.
    SARWER-FONER GJ
    Can Med Assoc J; 1960 Aug; 83(7):312-8. PubMed ID: 14441855
    [No Abstract]   [Full Text] [Related]  

  • 32. A HYPOTHESIS CONCERNING A SITE OF ACTION OF TRANQUILIZING DRUGS AND THE SIGNIFICANCE OF ASSOCIATED EXTRAPYRAMIDAL MOTOR PHENOMENA.
    VENNING GR
    J New Drugs; 1963; 3(6):351-5. PubMed ID: 14113558
    [No Abstract]   [Full Text] [Related]  

  • 33. [Tranquilizing agents: extrapyramidal and antiparkinsonism activities].
    Bordeleau JM; Tétreault L; Elie R
    Vie Med Can Fr; 1972 Feb; 1(2):118-26. PubMed ID: 4637390
    [No Abstract]   [Full Text] [Related]  

  • 34. Procyclidine for dystonia caused by phenothiazine derivatives.
    PAULSON G
    Dis Nerv Syst; 1960 Aug; 21():447-8. PubMed ID: 14431032
    [No Abstract]   [Full Text] [Related]  

  • 35. [ON THE CLINICAL ASPECTS AND THERAPY OF PYRAMIDAL AND EXTRAPYRAMIDAL MOVEMENT DISORDERS].
    RETT A
    Wien Klin Wochenschr; 1963 Oct; 75():772-5. PubMed ID: 14093592
    [No Abstract]   [Full Text] [Related]  

  • 36. [Notes apropos of extrapyramidal type syndromes following psychotropic drugs and their corrective agents].
    BORENSTEIN P; DABBAH M; ROUSSEL A; BLES G
    Ann Med Psychol (Paris); 1962 May; 120(1)():947-9. PubMed ID: 13871269
    [No Abstract]   [Full Text] [Related]  

  • 37. [Contribution to the study of extrapyramidal syndromes following use of neuroleptics. Apropos of the use of 2 psychotropic substances with powerful neurotropic activity].
    BORENSTEIN P; DABBAH M; BLES G
    Ann Med Psychol (Paris); 1962 Feb; 120(1)():279-319. PubMed ID: 13871266
    [No Abstract]   [Full Text] [Related]  

  • 38. [ACTION OF ETHYBENZATROPINE ON EXTRAPYRAMIDAL SYNDROMES AND ABNORMAL MOVEMENTS].
    SIGWALD J; RAVERDY P; PIOT C
    Presse Med (1893); 1963 Dec; 71():2643-4. PubMed ID: 14102418
    [No Abstract]   [Full Text] [Related]  

  • 39. [Present-day possibilities of relieving post-neuroleptic extrapyramidal symptoms].
    Wasik A
    Psychiatr Pol; 1973; 7(1):51-6. PubMed ID: 4715833
    [No Abstract]   [Full Text] [Related]  

  • 40. TREATMENT OF DRUG-INDUCED PARKINSONISM: A COMPARISON BETWEEN UK-738, ORPHENADRINE, AND A PLACEBO IN A DOUBLE BLIND STUDY.
    JENSEN K; AMDISEN A
    Psychopharmacologia; 1964 Mar; 5():301-5. PubMed ID: 14143342
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.